CWS
BCRX icon

Cypress Wealth Services’s BioCryst Pharmaceuticals BCRX Stock Holding History

Cypress Wealth Services’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-15,000
Closed -$52K – 307
2020
Q3 		$52K Buy
+15,000
New +$64.3K 0.01% 264

Other funds holding BCRX

OAM
OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
QFW
QTR Family Wealth Lake Mary, Florida $287M AUM 40.55% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CV
Counterweight Ventures Wilmington, North Carolina $201M AUM 35.56% 1-Year Est. Return

Cypress Wealth Services's BCRX Position: Q2 2026 in Review

Cypress Wealth Services held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 20,000 shares worth $200K. The position accounts for 0.02% of the portfolio, ranked #413.

Cypress Wealth Services first reported a position in BCRX in Q1 2020 and has held it in 25 quarters since. The position peaked at $325K in Q1 2022. 52 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Cypress Wealth Services held 20,000 shares of BioCryst Pharmaceuticals worth $200K as of Q2 2026.
  • Cypress Wealth Services left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
  • BioCryst Pharmaceuticals made up 0.02% of Cypress Wealth Services's portfolio in Q2 2026, its #413 holding.
  • Cypress Wealth Services first reported a position in BioCryst Pharmaceuticals in Q1 2020 and has held it in 25 quarters since.
  • Cypress Wealth Services's BioCryst Pharmaceuticals position peaked at $325K in Q1 2022.
  • 52 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Cypress Wealth Services's 13F filing for Q2 2026, filed 13 Jul 2026.